title: The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier.
abstract: Anterior chamber fluorophotometry was performed after the oral administration of fluorescein sodium in patients undergoing extracapsular cataract extraction and posterior chamber intraocular lens insertion before and after surgery. The administration of 0.5% ketorolac tromethamine solution (ketorolac solution) eye drops before and after surgery decreased the breakdown of the blood-aqueous barrier as compared with 0.1% dexamethasone sodium phosphate solution (dexamethasone solution) eye drops at each period, as measured by fluorophotometry. A single injection below Tenon's capsule of a short-acting corticosteroid had been given to each patient at the end of each surgical procedure. Slit-lamp observations of postoperative ocular inflammation were not different between treatment groups. Both ketorolac and dexamethasone solutions were well tolerated by patients. Ketorolac solution was more effective than dexamethasone solution in facilitating reestablishment of the blood-aqueous barrier after surgery, as measured by fluorophotometry, and was equal to dexamethasone solution as observed by slit-lamp observations. This study suggests that ketorolac ophthalmic solution may be effective and safe as a nonsteroidal anti-inflammatory agent for topical use after cataract surgery and intraocular lens implantation in place of topically administered corticosteroids.
authors: Department of Ophthalmology, University of California, San Francisco Medical Center.
authors: A J
authors: AJ
authors: Flach
authors: M C
authors: MC
authors: Kraff
authors: D R
authors: DR
authors: Sanders
authors: L
authors: L
authors: Tanenbaum
mesh_terms: D000328:Adult; D001082:Aqueous Humor / Q000378:metabolism*; D002199:Capillary Permeability / Q000187:drug effects*; D002387:Cataract Extraction; D003907:Dexamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D005123:Eye / Q000098:blood supply*; D005260:Female; D005470:Fluorometry; D006801:Humans; D020911:Ketorolac Tromethamine; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D010783:Photometry; D011184:Postoperative Period; D011758:Pyrroles / Q000627:therapeutic use*; D012996:Solutions; D014046:Tolmetin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014325:Tromethamine / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D011758:Pyrroles; D012996:Solutions; D014325:Tromethamine; C004180:dexamethasone 21-phosphate; D020911:Ketorolac Tromethamine; D003907:Dexamethasone; D014046:Tolmetin